Neurotrophin-3 improves functional constipation

Area of Science:

• Neuroscience
• Gastroenterology
• Pharmacology

Background:

• Neurotrophin-3 (NT-3) is a key neurotrophic factor regulating nervous system development and function.
• Preliminary research indicated NT-3's potential to enhance gastrointestinal (GI) transit and stool frequency.
• Chronic constipation affects a significant population, necessitating novel therapeutic approaches.

Purpose of the Study:

• To evaluate the dose-dependent effects of NT-3 on bowel function and colon transit in patients with chronic constipation.
• To assess the efficacy of NT-3 in improving symptoms associated with chronic constipation.
• To determine the safety profile of NT-3 administration.

Main Methods:

• A double-blind, randomized, placebo-controlled phase II study involving 107 patients diagnosed with functional constipation.
• Participants received subcutaneous injections of placebo or varying doses of NT-3 (3 mg or 9 mg) once or three times weekly for four weeks.
• Primary endpoint: change in spontaneous, complete bowel movements per week. Colon transit was assessed pre- and post-treatment.

Main Results:

• The 9 mg NT-3 administered three times weekly (TTW) significantly increased spontaneous and total bowel movement frequency compared to placebo.
• A dose-related improvement in stool consistency and ease of passage was observed with NT-3 TTW.
• NT-3 TTW reduced infrequent bowel movements, improved colon transit, alleviated constipation symptoms, and showed transient injection-site reactions as the most common adverse event.

Conclusions:

• Administering NT-3 three times weekly (TTW) effectively enhances stool frequency and colon transit in patients with chronic constipation.
• NT-3 demonstrates significant improvement in constipation-related symptoms.
• NT-3 represents a potentially novel, safe, and effective therapeutic agent for functional constipation.